260
Participants
Start Date
July 10, 2025
Primary Completion Date
April 4, 2028
Study Completion Date
April 4, 2028
CSL889
CSL889 is a solution for infusion to be administered by the IV route.
Placebo
Volume and regimen matched to CSL899 will be administered.
UZ Leuven - Centrum voor Moleculaire en Vasculaire Biologie, Leuven
CHR de la Citadelle, Liège
Mount Sinai Medical Center, New York
Jacobi Medical Center, The Bronx
Albert Einstein College of Medicine, The Bronx
University of Maryland, Baltimore
Golisano Children's Hospital, Fort Myers
Istanbul Universitesi - Cocuk Sagligi Enstitusu (Institute of Child Health), Istanbul
AOUI Verona and University of Verona, Verona
The Ohio State University, Columbus
University of Cincinnati, Cincinnati
Henry Ford Health System, Detroit
University of California Irvine, Orange
The Foundation for Sickle Cell Disease, Hollywood
Hospital Sant Joan de Déu, Barcelona
Hacettepe Universitesi - Hacettepe Universitesi Hastaneleri, Ankara
Özel Acibadem Adana Hastanesi, Seyhan
Lead Sponsor
CSL Behring
INDUSTRY